EPCORE DLBCL-2
Tests whether adding a bispecific to first-line chemotherapy cures more patients up front.
Fixed-duration epcoritamab with R-CHOP; topline results were announced in 2026 and presented at EHA 2026. Together with frontMIND and POLARIX, it defines the frontline options for higher-risk disease.
Setting
Untreated DLBCL: epcoritamab + R-CHOP vs R-CHOP
Phase
Phase 3
Sponsor
Genmab / AbbVie
Registry